(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.26%) $78.31
(0.19%) $2.15
(0.43%) $2 318.50
(1.76%) $27.16
(-0.59%) $959.60
(0.03%) $0.929
(-0.04%) $10.87
(0.01%) $0.797
(0.00%) $91.45
Live Chart Being Loaded With Signals
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China...
Stats | |
---|---|
今日成交量 | 216 000 |
平均成交量 | 99 912.00 |
市值 | 487.89M |
EPS | HKD0 ( 2023-08-30 ) |
Last Dividend | HKD0.00980 ( 2023-05-31 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 24.00 |
ATR14 | HKD0 (0.00%) |
Sinco Pharmaceuticals 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Sinco Pharmaceuticals 财务报表
Annual | 2022 |
营收: | HKD2.27B |
毛利润: | HKD305.87M (13.47 %) |
EPS: | HKD0.0342 |
FY | 2022 |
营收: | HKD2.27B |
毛利润: | HKD305.87M (13.47 %) |
EPS: | HKD0.0342 |
FY | 2021 |
营收: | HKD2.02B |
毛利润: | HKD364.95M (18.03 %) |
EPS: | HKD0.0800 |
FY | 2020 |
营收: | HKD2.05B |
毛利润: | HKD273.83M (13.36 %) |
EPS: | HKD0.0700 |
Financial Reports:
No articles found.
Sinco Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.00980 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00330 | 2016-09-09 |
Last Dividend | HKD0.00980 | 2023-05-31 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | HKD0.0131 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.34 | -- |
Div. Sustainability Score | 9.62 | |
Div.Growth Potential Score | 4.53 | |
Div. Directional Score | 7.08 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9987.HK | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
2192.HK | Ex Dividend Junior | 2023-11-07 | Annually | 0 | 0.00% | |
1193.HK | Ex Dividend Knight | 2023-05-30 | Semi-Annually | 0 | 0.00% | |
0257.HK | Ex Dividend Junior | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
3933.HK | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% | |
1766.HK | Ex Dividend Junior | 2023-06-21 | Annually | 0 | 0.00% | |
0808.HK | Ex Dividend Junior | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
2356.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1319.HK | Ex Dividend Knight | 2023-08-02 | Semi-Annually | 0 | 0.00% | |
0382.HK | Ex Dividend Knight | 2023-05-10 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0122 | 1.500 | 9.76 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0165 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0449 | 1.500 | -0.612 | -0.919 | [0.1 - 1] |
payoutRatioTTM | 0.668 | -1.000 | 3.32 | -3.32 | [0 - 1] |
currentRatioTTM | 1.183 | 0.800 | 9.08 | 7.27 | [1 - 3] |
quickRatioTTM | 0.818 | 0.800 | 9.90 | 7.92 | [0.8 - 2.5] |
cashRatioTTM | 0.517 | 1.500 | 8.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.125 | -1.500 | 7.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.203 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.180 | 2.00 | 9.91 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.339 | -1.500 | 8.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.119 | 1.000 | -1.345 | -1.345 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0343 | 1.000 | -1.314 | -1.314 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.01 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 1.359 | 0.800 | 4.27 | 3.42 | [0.5 - 2] |
Total Score | 9.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 16.64 | 1.000 | 8.42 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0449 | 2.50 | -0.394 | -0.919 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.180 | 2.00 | 9.94 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.41 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.203 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.668 | 1.500 | 3.32 | -3.32 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.185 | 1.000 | 7.87 | 0 | [0.1 - 0.5] |
Total Score | 4.53 |
Sinco Pharmaceuticals
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。